12-01 :: January 2012
nanotimes
Companies Facts
on of VelQuest extends Accelrys‘ software portfolio into the downstream pharmaceutical development Quality Assurance and Quality Control (QA/QC) space, offering significant productivity improvements, faster cycle times, lower operational costs and re- duced compliance risks for regulated life sciences organizations.
http://www.accelrys.com
and registration of insulins, including analogue insulins. Within the framework of the joint-venture, Bioton will be responsible for the development and manufacture of insulin products, while Actavis will be granted an exclusive licence to commercialise those products under the Actavis brand throughout the European Union and the United States of America, as well as in Albania, Bosnia & Herzegovina, Croatia, Iceland, Japan, Kosovo, Lichtenstein, Macedonia, Montenegro, Norway, Serbia and Switzerland.
A
http://www.actavis.com http://www.bioton.pl/en
1-for-10 reverse stock split of the Company’s com- mon stock at its Special Meeting of Stockholders held today.
A
http://www.acusphere.com
cusphere, Inc. (
ACUS.PK) announced that its stockholders voted to approve the proposed
ctavis and Bioton (WSE:BIO) have formed a joint venture company for the development
Research and Development Agreement (CRADA) with the US Air Force Research Laboratory (AFRL), Materials and Manufacturing Directorate, Airbase Technologies Division, Tyndall AFB, Florida to continue to develop and commercialize the paten- ted and award winning Reactive Surface Treatment (RST) technology. This collaboration is a joint effort that will explore the RST technology on a variety of materials, integrate nanoparticles developed by the Air Force in various RST treatment applications, and demonstrate a commercially feasible and scalable production process. The outcome of this activity is anticipated to result in greater soldier protection from chemical and biological threats and improved materials used in military and commercial applica- tions.
A
Moreover, Alexium International has commenced trading on the OTC markets prestigious tier, OTCQX International. The quotation is now active on the OTCQX website and can be found by searching un- der Alexium code of AXXIY.
Alexium also announced it is forging ahead with Bruck Textiles on several joint development projects and license negotiations for the Australasia region. While the product developments and negotiations are covering a broader spectrum of fabrics, Alexium and Bruck are already engaged in performance trials for ballistic fabrics treated with Alexium’s repellency treatment. Importantly, Alexium’s RST repellency treatments do not contain perfluorooctanoic acids (PFOAs) or perfluorooctanesulfonic acids (PFOSs), which are currently used by other traditional repel- lency treatments, and which are now being phased
lexium International Group Limited (ASX:AJX, OTC QX:AXXIY) has signed a new Cooperative
13
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97